N. Wu

PDB54 DULOXETINE THERAPY AND CHANGES IN OPIOID USE AMONG DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS

s A107 with target drugs. The purpose of this study was to ascertain whether revocation of the PA requirement resulted in inferior rates of HbA1C testing amongst new users of these drugs. METHODS: Data on of new users of the target drugs and on HbA1C testing in these patients was extracted from EPR databases for the six-month postrevocation period. The proportion of patients who performed at least one HbA1C test during the four months prior to initiation of treatment and 95% confi dence intervals were calculated. The data were stratifi ed by month to detect possible trends in rates of testing during the post policy-change period. RESULTS: After rescinding the PA requirement, HbA1C testing amongst incident users of the target drugs dropped from 100% during the PA period to rates of 85.6% (95% CI 79.7, 91.5) to 94.4% (95% CI 90.8, 97.9). Statistically signifi cant variance in monthly rates of testing was not observed. CONCLUSIONS: The PA requirement resulted in total performance of a lab test necessary to monitor drug-therapy outcomes in diabetic patients. When PA is implemented as a quality-assurance strategy, revocation should be accompanied by continuing-education efforts to maintain adherence to recommendations for appropriate care. PDB53 SHORT-TERM OUTCOMES FOR AN EMPLOYER SPONSERED PHARMACISTPROVIDED MULTI CENTER DIABETES MANAGEMENT PROGRAM